To address the unmet medical needs of our patients with paradigm-shifting therapeutics.
We derive our name from the latin word vincēre meaning
VIP152 inhibits PTEFb phosphorylation of RNA polymerase II (RNAPII), thereby preventing transcription elongation and blocking expression of genes that drive cancer.
Vincerx Pharma To Host Key Opinion Leader Webinar on VIP152 for the Treatment of Hematologic and Solid Tumors
PALO ALTO, Calif. , Feb. 24, 2021 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced that it will be hosting a key opinion leader (KOL)